- Home
- SNT vs WHWK Comparison
SNT vs WHWK Comparison
Compare SNT & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNT | WHWK |
|---|---|---|
| Founded | 1965 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.2M | 95.2M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | SNT | WHWK |
|---|---|---|
| Price | $3.87 | $2.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 32.5K | ★ 125.8K |
| Earning Date | 11-25-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 257.88 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $37,837,000.00 | $14,384,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.26 | ★ N/A |
| Revenue Growth | ★ 9.82 | N/A |
| 52 Week Low | $2.57 | $1.39 |
| 52 Week High | $5.34 | $3.77 |
Technical Indicators
Market Signals| Indicator | SNT | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 50.16 |
| Support Level | $3.70 | $2.69 |
| Resistance Level | $4.01 | $2.83 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 21.18 | 27.50 |
Price Performance
Historical ComparisonAbout SNT Senstar Technologies Ltd.
Senstar Technologies Corp is a provider of comprehensive physical, video, and access control security products and solutions. Its perimeter intrusion detection systems (including fence sensors, buried sensors, and above-ground sensors), intelligent video management, video analytics, and access control offer a comprehensive suite of integrated solutions that reduce complexity, improve performance, and unify support.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.